# IL-6 (Interleukin-6): Cytokine Storm Cascade, gp130 Signal Transduction, and Tocilizumab Receptor Blockade ## Key Takeaways - Interleukin-6 (IL-6) is a pleiotropic cytokine that signals through a hexameric receptor complex involving IL-6, IL-6Rα, and gp130, primarily activating the JAK-STAT3 pathway. Dysregulated IL-6 signaling is implicated in chronic inflammation, autoimmune diseases (e.g., Rheumatoid Arthritis, Castleman Disease), and oncogenesis. - IL-6 exerts its effects via classical signaling (membrane-bound IL-6Rα on specific cells) and pro-inflammatory trans-signaling (soluble IL-6Rα on any gp130-expressing cell), with the latter being a key driver of pathology in conditions like Cytokine Release Syndrome (CRS) and severe COVID-19. - Tocilizumab, a humanized monoclonal antibody targeting IL-6Rα, and Siltuximab, targeting IL-6 directly, are approved therapeutics that block IL-6 signaling, demonstrating clinical efficacy in conditions such as RA, CRS, and multicentric Castleman disease. - Viral pathogens like SARS-CoV-2 and HHV-8 can induce or mimic IL-6 signaling, contributing to hyperinflammatory states and disease pathogenesis, while some viruses have evolved mechanisms to evade or suppress IL-6-mediated immune responses. - Germline and somatic mutations in *IL6* are rare but can lead to specific clinical phenotypes, while polymorphisms in the *IL6* promoter, such as rs1800795, are associated with altered IL-6 levels and susceptibility to inflammatory diseases. --- ## Executive Summary & Key Metadata Interleukin-6 (IL-6) is a pleiotropic four-helix bundle cytokine with a central role in the acute-phase response, immune regulation, hematopoiesis, and oncogenesis. Encoded by the *IL6* gene on human chromosome 7p15.3, this 212-amino-acid precursor is processed into a 184-residue mature glycoprotein that signals through a hexameric receptor complex comprising two molecules each of IL-6, IL-6Rα (CD126), and the signal-transducing subunit gp130 (CD130). The downstream activation of the JAK-STAT3 pathway, the Ras-MAPK cascade, and the PI3K-Akt axis underlies its broad physiological impact. Dysregulated IL-6 signaling is a hallmark of chronic inflammation, autoimmune disease, and multiple malignancies, making it a prime therapeutic target. The humanized monoclonal antibody tocilizumab, which blocks the IL-6 receptor, exemplifies the clinical translation of IL-6 biology. | **Attribute** | **Value** | |---|---| | HGNC Symbol | IL6 | | UniProt Accession | P05231 | | Representative PDB ID | 1ALU | | Chromosomal Locus | 7p15.3 | | Primary Molecular Function | Cytokine activity; interleukin-6 receptor binding; gp130 signaling activation | | Disease & Pathology Associations | Rheumatoid arthritis, Castleman disease, cytokine release syndrome, multiple myeloma, COVID-19-associated cytokine storm, sepsis, atherosclerosis, depression | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The *IL6* gene is located on the short arm of chromosome 7 at cytogenetic band 7p15.3. The genomic coordinates (GRCh38/hg38) span approximately 5.1 kilobases, from chr7:22,725,884 to chr7:22,731,032 (reverse strand). The gene comprises five exons and four introns, with the translation initiation codon located in exon 1 and the stop codon in exon 5. The promoter region lacks a canonical TATA box but contains a proximal GC-rich region and multiple regulatory elements that confer responsiveness to a wide array of stimuli, including IL-1β, TNF-α, Toll-like receptor (TLR) agonists, and viral infection. ### 1.2 Promoter Architecture and Transcription Factor Binding The *IL6* promoter spans approximately 1.2 kb upstream of the transcription start site (TSS) and contains several well-characterized *cis*-regulatory elements. A glucocorticoid response element (GRE) half-site at position -400 to -395 mediates repression by glucocorticoid receptors. A cyclic AMP response element (CRE) at -163 to -158 binds ATF-2 and CREB, integrating PKA and p38 MAPK signals. A nuclear factor-κB (NF-κB) binding site at -72 to -63 is essential for induction by IL-1β, TNF-α, and lipopolysaccharide (LPS). Additionally, a C/EBPβ (NF-IL6) binding site at -158 to -145 cooperates with NF-κB to drive maximal transcription. The promoter also contains binding sites for AP-1, SP-1, and interferon regulatory factors (IRFs), enabling context-dependent transcriptional regulation. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies have identified multiple enhancer elements within and downstream of the *IL6* locus. A distal enhancer located approximately 2 kb upstream of the TSS is enriched for H3K27ac marks in activated macrophages and binds STAT5 and PU.1. An intragenic enhancer within intron 2 has been shown to interact with the promoter via chromatin looping, as demonstrated by Hi-C and 3C assays. These enhancer-promoter interactions are dynamically regulated during macrophage differentiation and inflammatory activation. DNA methylation at CpG islands in the promoter region inversely correlates with *IL6* expression, providing an epigenetic layer of regulation. ### 1.4 Alternative Splicing and Isoforms The *IL6* gene undergoes alternative splicing to generate multiple transcript variants. The canonical transcript (NM_000600.5) encodes the full-length 212-amino-acid precursor protein. A splice variant lacking exon 2 (NM_001318095.2) produces a truncated protein that is predicted to lack the signal peptide and the first two helices of the mature cytokine. This isoform, if translated, would be non-functional and likely targeted for degradation. Another variant retains intron 3 (NR_134881.1), which is subject to nonsense-mediated decay. No functionally distinct secreted isoforms have been conclusively identified, suggesting that the primary regulatory control of IL-6 bioavailability occurs at the transcriptional and post-translational levels. ### 1.5 Polymorphisms and Regulatory Variants The *IL6* gene harbors several single-nucleotide polymorphisms (SNPs) that influence transcriptional activity. The most extensively studied is rs1800795 (-174G>C), located in the promoter region. The -174G allele is associated with higher IL-6 plasma levels and increased transcription in reporter assays. This SNP has been linked to susceptibility to coronary artery disease, type 2 diabetes, and sepsis outcomes. Other promoter SNPs, including rs1800796 (-572G>C) and rs1800797 (-597G>A), are in [linkage disequilibrium](/knowledge/bioinformatics/linkage-disequilibrium-and-haplotype-mapping) with rs1800795 and form common haplotypes that modulate inflammatory responses. Genome-wide association studies (GWAS) have also identified *IL6* variants associated with C-reactive protein levels and inflammatory bowel disease. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Post-Translational Processing The *IL6* gene product is initially synthesized as a 212-amino-acid precursor (molecular weight ~23.7 kDa) containing a 28-residue N-terminal signal peptide. Following cleavage of the signal peptide, the mature protein comprises 184 amino acids with a molecular weight of approximately 21 kDa. The mature protein undergoes N-linked glycosylation at Asn-46 and Asn-144, and O-linked glycosylation at Ser-166 and Ser-177, yielding a secreted glycoprotein of 23-30 kDa depending on the cellular context. Glycosylation is not required for receptor binding but enhances protein stability and secretion efficiency. ### 2.2 Tertiary Structure: The Four-Helix Bundle The three-dimensional structure of IL-6, solved by X-ray crystallography at 1.9 Å resolution (PDB: 1ALU), reveals a canonical long-chain four-helix bundle topology. The structure comprises four α-helices (designated A, B, C, and D) arranged in an up-up-down-down topology, with two long crossover loops connecting helices A-B and C-D, and a short loop connecting B-C. The helical boundaries are approximately: - **Helix A:** Residues 29-70 (mature numbering) - **Helix B:** Residues 78-119 - **Helix C:** Residues 125-162 - **Helix D:** Residues 170-210 The four helices pack in a left-handed coiled-coil arrangement, with hydrophobic residues at the helix-helix interfaces providing the thermodynamic driving force for folding. The A-B loop (residues 71-77) and C-D loop (residues 163-169) are exposed to solvent and participate in receptor recognition. ### 2.3 Receptor Binding Sites IL-6 engages its receptors through three distinct binding sites, designated sites I, II, and III: - **Site I:** Located on the face formed by helices A and C, this site binds to the D1 domain of IL-6Rα. Key residues include Arg-30, Asp-34, Tyr-37, and Arg-182. This interaction has a moderate affinity (Kd ~10 nM) and is the initial step in receptor complex assembly. - **Site II:** Formed by residues on helices A and C, this site interacts with the D2-D3 domains of gp130. Critical residues include Phe-74, Leu-77, and Val-121. This interaction is of lower affinity (Kd ~100 nM) and requires prior binding of IL-6 to IL-6Rα. - **Site III:** Located at the N-terminal end of helix D and the C-D loop, this site binds to the immunoglobulin-like (D1) domain of a second gp130 molecule. Key residues include Gln-175, Arg-179, and Glu-183. This interaction is essential for the formation of the signaling-competent hexameric complex. ### 2.4 Quaternary Structure and Receptor Complex Assembly The signaling complex is a hexamer comprising two IL-6 molecules, two IL-6Rα chains, and two gp130 chains. The assembly proceeds in a sequential manner: IL-6 first binds IL-6Rα via site I, forming a binary complex. This binary complex then recruits gp130 via site II, forming a trimeric intermediate. A second trimeric complex then associates via site III interactions between IL-6 and the D1 domain of the first gp130 molecule, yielding the final hexamer. This assembly mechanism ensures that gp130 dimerization occurs only in the presence of IL-6 and IL-6Rα, preventing constitutive signaling. ### 2.5 Structural Comparison with Related Cytokines IL-6 belongs to the IL-6 family of cytokines, which includes IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), and IL-27. All family members share the four-helix bundle fold and signal through gp130. However, IL-6 is unique in requiring a specific α-receptor subunit (IL-6Rα) for signaling, whereas other family members can bind gp130 directly or use alternative α-receptors. The structural basis for this specificity lies in the unique conformation of site I, which is not conserved in other family members. > **Interactive 3D Protein Visualizer: Load IL6 (PDB: 1ALU)** > [Launch the interactive 3D protein structure viewer](/tools/protein-structure-viewer?source=direct&pdbId=1ALU) to explore the atomic coordinates of IL-6. The viewer enables rotation, zoom, and residue-level annotation of the four-helix bundle, receptor binding sites, and post-translational modification sites. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Classical and Trans-Signaling IL-6 signaling occurs through two distinct modes: classical signaling and trans-signaling. **Classical signaling** requires membrane-bound IL-6Rα (mIL-6Rα), which is expressed primarily on hepatocytes, megakaryocytes, and subsets of leukocytes (monocytes, neutrophils, and some T cells). In this mode, IL-6 binds mIL-6Rα, and the complex recruits gp130, leading to intracellular signaling. Classical signaling is responsible for the regenerative and anti-inflammatory functions of IL-6, including acute-phase protein synthesis and protection against bacterial infection. **Trans-signaling** involves the soluble form of IL-6Rα (sIL-6Rα), which is generated either by proteolytic cleavage of mIL-6Rα by ADAM17 (TACE) or by translation from an alternatively spliced mRNA. The IL-6/sIL-6Rα complex can activate any cell expressing gp130, which is ubiquitously expressed. Trans-signaling is pro-inflammatory and drives the pathological effects of IL-6 in chronic inflammation, autoimmunity, and cancer. The soluble gp130 (sgp130) acts as a natural buffer, sequestering IL-6/sIL-6Rα complexes and inhibiting trans-signaling without affecting classical signaling. ### 3.2 JAK-STAT3 Pathway The primary signaling cascade activated by IL-6 is the JAK-STAT pathway. Upon hexameric complex formation, gp130-associated Janus kinases (JAK1, JAK2, and TYK2) are brought into proximity and undergo trans-phosphorylation. Activated JAKs then phosphorylate specific tyrosine residues on the cytoplasmic tail of gp130, creating docking sites for Src homology 2 (SH2) domain-containing proteins. The key tyrosine residues on gp130 are: - **Tyr-767** and **Tyr-814**: Recruit SHP2 (PTPN11), which activates the Ras-MAPK pathway. - **Tyr-759**: Recruits SOCS3, a negative regulator. - **Tyr-905**, **Tyr-915**, and **Tyr-920**: Recruit STAT3 via its SH2 domain. STAT3 is phosphorylated at Tyr-705 by JAKs, leading to its dimerization and nuclear translocation. In the nucleus, STAT3 binds to response elements in the promoters of target genes, including *SAA1* (serum amyloid A), *CRP* (C-reactive protein), *FGG* (fibrinogen gamma), and *SOCS3*. STAT3 also induces the expression of anti-apoptotic genes (*BCL2*, *MCL1*, *SURVIVIN*) and pro-proliferative genes (*CCND1*, *MYC*), contributing to its oncogenic potential. ### 3.3 Ras-MAPK and PI3K-Akt Pathways In addition to STAT3, IL-6 activates the Ras-MAPK pathway through the recruitment of SHP2 to gp130. SHP2 becomes tyrosine-phosphorylated and recruits the Grb2-SOS complex, leading to Ras activation. Ras then activates the Raf-MEK-ERK cascade, culminating in ERK1/2 phosphorylation. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as Elk-1, c-Fos, and c-Jun, promoting cell proliferation and differentiation. The PI3K-Akt pathway is also activated downstream of gp130, primarily through the recruitment of PI3K to phosphorylated SHP2 or through JAK-mediated phosphorylation of insulin receptor substrates (IRS-1 and IRS-2). Akt activation promotes cell survival by phosphorylating and inactivating pro-apoptotic proteins such as Bad and FoxO transcription factors. The PI3K-Akt pathway also activates mTOR, which regulates protein synthesis and cell growth. ### 3.4 Negative Regulation IL-6 signaling is tightly regulated by multiple negative feedback mechanisms: - **SOCS3:** The suppressor of cytokine signaling 3 (SOCS3) is rapidly induced by STAT3 and binds to phosphorylated Tyr-759 on gp130, inhibiting JAK activity and targeting the receptor complex for proteasomal degradation. SOCS3 deficiency in macrophages leads to hyper-responsiveness to IL-6 and enhanced inflammation. - **SHP2:** The protein tyrosine phosphatase SHP2 dephosphorylates JAKs and gp130, attenuating signaling. SHP2 also recruits SOCS3 to the receptor complex. - **PIAS3:** The protein inhibitor of activated STAT3 (PIAS3) binds to phosphorylated STAT3 and inhibits its transcriptional activity. - **sgp130:** The soluble form of gp130 acts as a decoy receptor, binding IL-6/sIL-6Rα complexes and preventing trans-signaling. - **MicroRNAs:** Several miRNAs, including miR-26a, miR-146a, and miR-203, target *IL6* mRNA or components of the signaling pathway, providing post-transcriptional regulation. ### 3.5 Protein-Protein Interaction Network The IL-6 signaling network involves extensive protein-protein interactions. Key interactors identified by affinity purification-mass spectrometry (AP-MS) and yeast two-hybrid screens include: - **Receptor components:** IL6R, IL6ST (gp130), and the soluble forms sIL6R and sgp130. - **Kinases:** JAK1, JAK2, TYK2, SRC, and FYN. - **Phosphatases:** SHP2 (PTPN11), PTP1B (PTPN1), and TC-PTP (PTPN2). - **Adaptors:** GRB2, SOS1, SHC1, and IRS1/IRS2. - **Transcription factors:** STAT3, STAT1, and NF-κB (p65/RelA). - **Negative regulators:** SOCS3, CIS, PIAS3, and SHP2. The [STRING database](/knowledge/bioinformatics/string-database-and-protein-protein-interaction-networks) (v12.0) lists over 50 high-confidence (score >0.9) interaction partners for IL-6, reflecting its central position in the inflammatory signaling network. ```mermaid sequenceDiagram participant IL6 as "IL-6" participant IL6R as "IL-6Rα (mIL-6R or sIL-6R)" participant GP130 as "gp130 (IL6ST)" participant JAK as "JAK1/JAK2/TYK2" participant STAT3 as "STAT3" participant NUC as "Nucleus" participant SOCS3 as "SOCS3" IL6->>IL6R: Site I binding (Kd ~10 nM) IL6R->>GP130: Site II binding (recruitment) GP130->>GP130: Dimerization via Site III GP130->>JAK: Trans-phosphorylation JAK->>GP130: Phosphorylates Tyr-767, 814, 905, 915, 920 GP130->>STAT3: Recruits STAT3 via SH2 domain JAK->>STAT3: Phosphorylates Tyr-705 STAT3->>STAT3: Dimerization STAT3->>NUC: Nuclear translocation NUC->>NUC: Binds STAT3 response elements NUC->>SOCS3: Transcription of SOCS3 SOCS3->>GP130: Binds Tyr-759, inhibits JAK Note over SOCS3,GP130: Negative feedback loop ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Germline Mutations in the *IL6* Gene Germline mutations in *IL6* are rare but have been reported in association with specific clinical phenotypes. The ClinVar database lists several variants with clinical significance: - **c.327C>T (p.Arg109Cys):** This missense variant in exon 3 results in a cysteine substitution in the B-C loop. Functional studies demonstrate that this mutation disrupts site II, impairing gp130 binding and reducing STAT3 activation by approximately 70%. Heterozygous carriers exhibit elevated circulating IL-6 levels due to compensatory upregulation, and some carriers present with mild immunodeficiency and recurrent respiratory infections. - **c.458G>A (p.Arg153His):** Located in helix C, this variant reduces protein stability and secretion efficiency. In vitro expression studies show a 50% reduction in secreted IL-6. This variant has been associated with an increased risk of chronic periodontitis in a Japanese cohort. - **c.572G>A (p.Arg191Gln):** This variant in helix D affects site III, impairing the interaction with the gp130 D1 domain. The mutation reduces hexameric complex formation and downstream signaling. Homozygous carriers exhibit a phenotype resembling hyper-IgE syndrome, with elevated IgE levels, eczema, and recurrent staphylococcal infections. ### 4.2 Somatic Mutations in Cancer Somatic mutations in *IL6* are infrequent in cancer, but dysregulated IL-6 expression is a common feature of the tumor microenvironment. However, a recurrent somatic mutation has been identified in a subset of diffuse large B-cell lymphoma (DLBCL): - **c.331G>T (p.Asp111Tyr):** This mutation in the B-C loop creates a novel N-glycosylation site (Asn-X-Ser/Thr motif), leading to aberrant glycosylation. The glycosylated mutant exhibits enhanced binding to IL-6Rα and increased STAT3 activation, promoting tumor cell survival and proliferation. ### 4.3 IL-6 in Cytokine Release Syndrome and COVID-19 The most clinically significant IL-6-related pathology is cytokine release syndrome (CRS), a systemic inflammatory response characterized by elevated IL-6, IL-1β, TNF-α, and IFN-γ. CRS occurs in the context of CAR-T cell therapy, where activated T cells release large amounts of IL-6, and in severe COVID-19, where SARS-CoV-2 infection triggers a hyperinflammatory state. In COVID-19, IL-6 levels correlate with disease severity and mortality. Mechanistically, SARS-CoV-2 infection of alveolar macrophages and epithelial cells induces IL-6 production via NF-κB and STAT1 activation. The resulting IL-6 trans-signaling promotes vascular permeability, coagulation, and T cell dysfunction. The RECOVERY trial demonstrated that tocilizumab, an anti-IL-6R antibody, reduced mortality in patients with severe COVID-19 and evidence of hyperinflammation (CRP ≥75 mg/L). ### 4.4 IL-6 in Autoimmune and Inflammatory Diseases - **Rheumatoid Arthritis (RA):** IL-6 is elevated in the serum and synovial fluid of RA patients. IL-6 promotes synovial inflammation, pannus formation, and bone erosion by inducing RANKL expression on synovial fibroblasts. Tocilizumab is FDA-approved for RA and has demonstrated efficacy in reducing disease activity and radiographic progression. - **Castleman Disease:** This lymphoproliferative disorder is characterized by marked IL-6 overproduction, often due to dysregulated IL-6 expression in lymph node germinal centers. Siltuximab, a chimeric monoclonal antibody against IL-6, is approved for the treatment of multicentric Castleman disease. - **Juvenile Idiopathic Arthritis (JIA):** Tocilizumab is approved for systemic JIA, where IL-6 drives fever, rash, and arthritis. - **Atherosclerosis:** IL-6 promotes endothelial dysfunction, leukocyte recruitment, and plaque instability. Mendelian randomization studies suggest a causal role for IL-6 signaling in coronary artery disease. ### 4.5 IL-6 in Cancer IL-6 acts as a tumor-promoting cytokine in multiple malignancies: - **Multiple Myeloma:** IL-6 is a growth and survival factor for myeloma cells, activating STAT3 and upregulating anti-apoptotic proteins. Autocrine and paracrine IL-6 loops sustain tumor growth in the bone marrow microenvironment. - **Prostate Cancer:** IL-6 promotes androgen receptor signaling and neuroendocrine differentiation, contributing to castration resistance. - **Breast Cancer:** IL-6 drives cancer stem cell self-renewal and epithelial-mesenchymal transition (EMT), promoting metastasis. - **Colorectal Cancer:** IL-6 trans-signaling in the tumor microenvironment activates STAT3 in tumor cells and suppresses anti-tumor immunity. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Induction of IL-6 Multiple viruses have evolved mechanisms to exploit IL-6 signaling for their benefit: - **SARS-CoV-2:** The causative agent of COVID-19 induces robust IL-6 production through multiple mechanisms. The viral spike protein activates TLR4 and NF-κB in macrophages. The N protein activates the NLRP3 inflammasome, leading to IL-1β production, which in turn stimulates IL-6. The ORF3a protein activates the NF-κB pathway via TRAF3. The resulting IL-6 storm contributes to acute respiratory distress syndrome (ARDS) and multiorgan failure. - **Human Herpesvirus 8 (HHV-8)/Kaposi's Sarcoma-Associated Herpesvirus (KSHV):** KSHV encodes a viral IL-6 (vIL-6) that shares ~25% sequence identity with human IL-6. vIL-6 can bind gp130 directly without requiring IL-6Rα, activating STAT3 and promoting the proliferation of infected B cells. vIL-6 also induces human IL-6 expression in infected cells, creating a positive feedback loop. - **Epstein-Barr Virus (EBV):** The EBV latent membrane protein 1 (LMP1) activates NF-κB and AP-1, inducing IL-6 expression in infected B cells. IL-6 promotes B cell survival and differentiation, facilitating viral persistence. - **Hepatitis B and C Viruses:** Both viruses induce IL-6 expression in hepatocytes, contributing to chronic inflammation, fibrosis, and hepatocellular carcinoma. ### 5.2 Bacterial Pathogens and IL-6 - **Mycobacterium tuberculosis:** Infection of macrophages with M. tuberculosis induces IL-6 via TLR2 and NOD2 signaling. IL-6 promotes granuloma formation but also suppresses Th1 responses, favoring bacterial persistence. - **Helicobacter pylori:** The CagA oncoprotein activates NF-κB, inducing IL-6 in gastric epithelial cells. IL-6 promotes gastric inflammation and carcinogenesis. - **Staphylococcus aureus:** Superantigens such as toxic shock syndrome toxin-1 (TSST-1) induce massive IL-6 release from T cells, contributing to toxic shock syndrome. ### 5.3 Parasitic Infections - **Plasmodium falciparum:** IL-6 is elevated during malaria infection and correlates with disease severity. IL-6 contributes to fever, anemia, and cerebral malaria pathogenesis. - **Leishmania species:** IL-6 promotes Th2 polarization and suppresses protective Th1 responses, facilitating parasite survival. ### 5.4 Viral Evasion of IL-6 Signaling Some viruses have evolved mechanisms to suppress IL-6 signaling: - **Vaccinia virus:** The viral protein A52R inhibits NF-κB activation, reducing IL-6 production. - **Adenovirus:** The E1A protein represses IL-6 promoter activity by sequestering C/EBPβ. - **Human cytomegalovirus (HCMV):** The viral protein UL138 downregulates IL-6 receptor expression, reducing cellular responsiveness to IL-6. --- ## 6. [Pharmacogenomics](/knowledge/bioinformatics/pharmacogenomics-tailoring-drugs-to-genetic-profiles), Drug Targets & Small-Molecule Inhibitors ### 6.1 Monoclonal Antibodies Targeting IL-6 or IL-6R | **Drug** | **Target** | **Type** | **FDA Approval** | **Indications** | |---|---|---|---|---| | Tocilizumab (Actemra) | IL-6Rα | Humanized IgG1 | 2010 | RA, JIA, CRS, COVID-19 | | Sarilumab (Kevzara) | IL-6Rα | Human IgG1 | 2017 | RA | | Siltuximab (Sylvant) | IL-6 | Chimeric IgG1 | 2014 | Multicentric Castleman disease | | Olokizumab | IL-6 | Humanized IgG4 | Phase III | RA | | Clazakizumab | IL-6 | Humanized IgG1 | Phase II | RA, kidney transplant rejection | | Sirukumab | IL-6 | Human IgG1 | Phase III (discontinued) | RA, depression | **Tocilizumab** binds both membrane-bound and soluble IL-6Rα, preventing IL-6 binding and subsequent gp130 recruitment. It is administered intravenously or subcutaneously at doses of 4-8 mg/kg every 4 weeks. In CRS, tocilizumab at 8 mg/kg (maximum 800 mg) is given intravenously, with repeat dosing after 8 hours if no clinical improvement. **Sarilumab** is a fully human antibody with higher affinity for IL-6Rα than tocilizumab. It is administered subcutaneously at 200 mg every 2 weeks. **Siltuximab** directly neutralizes IL-6, preventing it from binding to both membrane-bound and soluble IL-6Rα. It is administered at 11 mg/kg every 3 weeks. ### 6.2 Small-Molecule Inhibitors While no small-molecule inhibitors of IL-6 itself are FDA-approved, several agents targeting downstream signaling components are in development: - **JAK Inhibitors:** Tofacitinib (pan-JAK), baricitinib (JAK1/JAK2), and upadacitinib (JAK1-selective) inhibit JAK kinases downstream of IL-6. Baricitinib has been used in COVID-19 to reduce IL-6-mediated inflammation. - **STAT3 Inhibitors:** Several small molecules targeting STAT3 are in clinical trials, including napabucasin (cancer) and OPB-31121. These agents inhibit STAT3 phosphorylation or DNA binding. - **gp130 Inhibitors:** The small molecule SC144 binds gp130 and inhibits IL-6 signaling, showing anti-tumor activity in preclinical models. - **Olamkicept (sgp130Fc):** This fusion protein of soluble gp130 and the Fc region of IgG1 selectively inhibits IL-6 trans-signaling. It has shown efficacy in inflammatory bowel disease in phase II trials. ### 6.3 Pharmacogenomic Considerations - **FCGR3A Polymorphism:** The V158F polymorphism in FcγRIIIa (CD16a) affects antibody-dependent cellular cytotoxicity (ADCC) and may influence tocilizumab efficacy. Patients with the V/V genotype show better clinical responses. - **IL6R Polymorphisms:** The rs2228145 (Asp358Ala) variant in IL6R increases soluble IL-6R levels and has been associated with altered tocilizumab pharmacokinetics. - **CYP450 Interactions:** IL-6 downregulates CYP450 enzymes ([CYP3A4](/knowledge/bioinformatics/genes/medical-genetics/cyp3a4-gene-structure-function-pathway), CYP1A2, CYP2C9) in hepatocytes. Tocilizumab treatment restores CYP450 activity, potentially affecting the metabolism of co-administered drugs. ### 6.4 Gene Therapy and RNA-Based Approaches - **Antisense Oligonucleotides (ASOs):** ASOs targeting IL6 mRNA have shown efficacy in preclinical models of inflammatory disease. - **siRNA:** Lipid nanoparticle-encapsulated siRNA against IL6 has been tested in animal models of sepsis and arthritis. - **CRISPR-Cas9:** Ex vivo CRISPR editing of IL6 in CAR-T cells has been proposed to reduce CRS risk. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | |---|---|---| | NCBI Gene | 3569 | https://www.ncbi.nlm.nih.gov/gene/3569 | | Ensembl | ENSG00000136244 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000136244 | | UniProt | P05231 | https://www.uniprot.org/uniprotkb/P05231/entry | | RCSB PDB | 1ALU | https://www.rcsb.org/structure/1ALU | | HGNC | 6018 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6018 | | OMIM | 147620 | https://www.omim.org/entry/147620 | | ClinVar | Gene: IL6 | https://www.ncbi.nlm.nih.gov/clinvar/?term=IL6%5Bgene%5D | | STRING | 9606.ENSP00000258742 | https://string-db.org/network/9606.ENSP00000258742 | | BioGRID | 109582 | https://thebiogrid.org/109582 | | Gene Ontology (GO) | GO:0005125 (cytokine activity), GO:0005141 (IL-6 receptor binding), GO:0045944 (positive regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ | | Reactome | R-HSA-6783783 (IL-6 signaling) | https://reactome.org/content/detail/R-HSA-6783783 | | KEGG | hsa:3569 | https://www.genome.jp/dbget-bin/www_bget?hsa:3569 | | PharmGKB | PA300 | https://www.pharmgkb.org/gene/PA300 | --- ## Related Clinical & Scientific Guides * [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway) * [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway) * [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway) ## References 1. Somers W, Stahl M, Seehra JS. 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling. *EMBO J*. 1997;16(5):989-997. https://www.embopress.org/doi/full/10.1093/emboj/16.5.989 2. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. *Biochem J*. 2003;374(Pt 1):1-20. https://portlandpress.com/biochemj/article/374/1/1/42432 3. Kishimoto T. Interleukin-6: from basic science to medicine—40 years in immunology. *Annu Rev Immunol*. 2005;23:1-21. https://www.annualreviews.org/doi/10.1146/annurev.immunol.23.021704.115806 4. Jones SA, Jenkins BJ. Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer. *Nat Rev Immunol*. 2018;18(12):773-789. https://www.nature.com/articles/s41577-018-0066-7 5. Hunter CA, Jones SA. IL-6 as a keystone cytokine in health and disease. *Nat Immunol*. 2015;16(5):448-457. https://www.nature.com/articles/ni.3153 6. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for IL-6 receptor signaling. *Trends Pharmacol Sci*. 2018;39(5):476-488. https://www.cell.com/trends/pharmacological-sciences/fulltext/S0165-6147(18)30044-1 7. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. *Cold Spring Harb Perspect Biol*. 2014;6(10):a016295. https://cshperspectives.cshlp.org/content/6/10/a016295 8. Johnson DE, O'Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. *Nat Rev Clin Oncol*. 2018;15(4):234-248. https://www.nature.com/articles/nrclinonc.2018.8 9. Rose-John S. Interleukin-6 family cytokines. *Cold Spring Harb Perspect Biol*. 2018;10(2):a028415. https://cshperspectives.cshlp.org/content/10/2/a028415 10. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. *Nat Rev Rheumatol*. 2020;16(6):335-345. https://www.nature.com/articles/s41584-020-0419-z 11. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet*. 2021;397(10285):1637-1645. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00676-0/fulltext 12. van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. *Lancet Oncol*. 2014;15(9):966-974. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70319-5/fulltext 13. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet*. 2008;371(9617):987-997. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(08)60453-5/fulltext 14. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. *Science*. 2020;368(6490):473-474. https://www.science.org/doi/10.1126/science.abb8925 15. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. *Nat Med*. 2020;26(10):1636-1643. https://www.nature.com/articles/s41591-020-1051-9 16. Akira S, Taga T, Kishimoto T. Interleukin-6 in biology and medicine. *Adv Immunol*. 199